Clinical trials: Epithelial Mesothelioma
Biphasic Mesothelioma, Epithelioid Mesothelioma
Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma
This phase I pilot trial studies how well atezolizumab, pemetrexed disodium, cisplatin, and surgery with or without radiation therapy works in treating patients with stage I-III pleural malignant mesothelioma.
- Conditions
- Biphasic Mesothelioma, Epithelioid Mesothelioma, Stage I Pleural Diffuse Malignant Mesothelioma AJCC v7, Stage IA Pleural Diffuse Malignant Mesothelioma AJCC v7
- Trial name
- NCT03228537
- Testing
- Atezolizumab, Cisplatin, Extrapleural Pneumonectomy
- Where
- 174 sites in United States
- Volunteers
- 28 people
- Sponsor
- National Cancer Institute (NCI)
Cancer
E-MOSAIC Electronic Tool to Monitor Symptoms
RATIONALE: A hand held electronic tool used to monitor symptoms and assess quality of life may improve communication between patients and their doctors and improve the ability to plan treatment for patients with advanced cancer…
- Trial name
- NCT00477919
- Where
- 7 sites in Switzerland
- Volunteers
- 264 people
- Sponsor
- Swiss Cancer Institute
Advanced Malignant Mesothelioma, Epithelial Mesothelioma
Gefitinib in Treating Patients With Malignant Mesothelioma
Phase II trial to study the effectiveness of gefitinib in treating patients who have malignant mesothelioma. Biological therapies such as gefitinib may interfere with the growth of the tumor cells and slow the growth of malignant…
- Conditions
- Advanced Malignant Mesothelioma, Epithelial Mesothelioma, Recurrent Malignant Mesothelioma, Sarcomatous Mesothelioma
- Trial name
- NCT00025207
- Testing
- gefitinib, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Pseudomyxoma Peritonei, Colorectal Carcinoma
Peritoneal Surface Malignancies - Characterization, Models and Treatment Strategies
The aim of this study is to identify biomarkers of disease recurrence and prognosis to optimize patient selection for treatment with cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC), and through…
- Conditions
- Pseudomyxoma Peritonei, Colorectal Carcinoma, Ovarian Carcinoma, Mesothelioma
- Trial name
- PSM (NCT02073500)
- Testing
- Observational study.
- Where
- Norway
- Volunteers
- 300 people
- Sponsor
- Oslo University Hospital
Malignant Pleural Mesothelioma
Galinpepimut-S (WT-1 Analog Peptide) Vaccine in Malignant Pleural Mesothelioma After Combined Modality Therapy
Study of galinpepimut-S, a Wilms Tumor-1 (WT1) vaccine, to see if it delays or prevents the mesothelioma from growing back after surgery. WT1 is a protein in cancer cells that regulates gene expression and causes cell growth.
- Trial name
- NCT01265433
- Testing
- Galinpepimut-S + Montanide + GM-CSF, Montanide + GM-CSF
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Sellas Life Sciences Group
Advanced Malignant Mesothelioma, Epithelial Mesothelioma
Erlotinib in Treating Patients With Malignant Mesothelioma of the Lung
Erlotinib may interfere with the growth of tumor cells and slow the growth of the tumor. This phase II trial is studying how well erlotinib works in treating patients with malignant mesothelioma of the lung
- Conditions
- Advanced Malignant Mesothelioma, Epithelial Mesothelioma, Recurrent Malignant Mesothelioma, Sarcomatous Mesothelioma
- Trial name
- NCT00039182
- Testing
- erlotinib hydrochloride, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- National Cancer Institute (NCI)
Pleural Mesothelioma, Treatment Response
Evaluation of Response by FLT PET in Mesothelioma
Pleural mesothelioma (MPM) is an aggressive tumor that affects the pleura and originates from mesothelial cells. If untreated, median survival is 4-12 months following diagnosis.
- Conditions
- Pleural Mesothelioma, Treatment Response, Chemotherapy Effect
- Trial name
- FLT-MM (NCT06410625)
- Testing
- FLT PET imaging
- Where
- Turkey (Türkiye)
- Volunteers
- 25 people
- Sponsor
- Ankara University
Advanced Malignant Mesothelioma, Epithelial Mesothelioma
Cediranib Maleate in Treating Patients With Malignant Mesothelioma That Cannot Be Removed By Surgery
This phase II trial is studying how well cediranib maleate works in treating patients with malignant mesothelioma that cannot be removed by surgery.
- Conditions
- Advanced Malignant Mesothelioma, Epithelial Mesothelioma, Localized Malignant Mesothelioma, Recurrent Malignant Mesothelioma
- Trial name
- NCT00309946
- Testing
- cediranib maleate
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- National Cancer Institute (NCI)
Mesothelioma
Study of Cytoreductive Surgery and Hyperthermic Intraoperative Chemotherapy With Pemetrexed and Cisplatin for MPM
Primary Objective To determine the maximum tolerated dose (MTD) of intrathoracic administration of pemetrexed when given in conjunction with cisplatin in patients with resectable malignant pleural mesothelioma MPM.
- Trial name
- NCT02838745
- Testing
- Pemetrexed, Cisplatin
- Where
- United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Baylor College of Medicine
Malignant Pleural Mesothelioma
Clinical Study of YS110 in Patients With Malignant Pleural Mesothelioma
The purpose of this study is to examine tolerability, safety, and pharmacokinetics of YS110 intravenous administration in patients with malignant pleural mesothelioma and to preliminarily examine the anti-tumor effect of YS110.
- Trial name
- NCT03177668
- Testing
- YS110
- Where
- Japan
- Volunteers
- 40 people
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
Mesothelioma, Malignant
Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma
This study will evaluate the combination of Nivolumab and Ramucirumab in patients with previously-treated mesothelioma.
- Trial name
- NCT03502746
- Testing
- Nivolumab, Ramucirumab
- Where
- 4 sites in United States
- Volunteers
- 34 people
- Sponsor
- Arkadiusz Z. Dudek, MD
Malignant Pleural Mesothelioma, Diagnoses Disease
Real World Study of MPM in China
Malignant pleural mesothelioma (MPM) is a highly aggressive tumor with atypical clinical manifestations. Most patients with MPM are at an advanced stage at the time of diagnosis, and only a few patients can be cured by radical…
- Conditions
- Malignant Pleural Mesothelioma, Diagnoses Disease, Treatments, Prognosis
- Trial name
- NCT05042557
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Chinese Academy of Medical Sciences
Colorectal Cancer Not MSI-H or MMR-deficient, GIST
A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors
Assessment of the efficacy and safety of Regorafenib and Avelumab in patients with advanced or metastatic solid tumors (ten cohorts), once the Recommanded Phase II Dose (RP2D) has been determined (phase I trial).
- Conditions
- Colorectal Cancer Not MSI-H or MMR-deficient, GIST, Oesophageal or Gastric Carcinoma, Biliary Tract Cancer
- Trial name
- REGOMUNE (NCT03475953)
- Testing
- Phase 1 : Regorafenib, Phase 1 : Avelumab, Phase 2 : Regorafenib
- Where
- 7 sites in France
- Volunteers
- 747 people
- Sponsor
- Institut Bergonié
Mesothelioma, Malignant Mesothelioma (MM)
Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma
This is a Phase II study to determine the rate of stabilization or disease improvement from investigational decitabine/cedazuridine (INQOVI) treatment in subjects with BRCA1-Associated Protein-1 (BAP1) Cancer Predisposition…
- Conditions
- Mesothelioma, Malignant Mesothelioma (MM), Early-stage Mesothelioma, Subclinical Mesothelioma
- Trial name
- NCT05960773
- Testing
- Decitabine/cedazuridine
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Malignant Pleural Mesothelioma
An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma
This research is being done to find out if pemetrexed and cisplatin work better when given together with an experimental drug called MORAb-009 in patients with malignant pleural mesothelioma.
- Trial name
- Amatuximab (NCT00738582)
- Testing
- MORAb-009 (Amatuximab), Pemetrexed, Cisplatin
- Where
- 28 sites in United States, Canada and 3 more
- Volunteers
- 89 people
- Sponsor
- Morphotek
Malignant Mesothelioma
Surgery, Chemotherapy, and Radiation Therapy in Treating Patients With Peritoneal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving the drugs directly into the tumor after surgery and combining them with radiation therapy may kill…
- Trial name
- NCT00024271
- Testing
- recombinant interferon gamma, cisplatin, doxorubicin hydrochloride
- Where
- United States
- Sponsor
- Herbert Irving Comprehensive Cancer Center
Malignant Pleural Mesothelioma
Intrapleural Administration of HSV1716 to Treat Patients With Malignant Pleural Mesothelioma.
HSV1716, an oncolytic virus, is a mutant herpes simplex virus (HSV) type I, deleted in the RL1 gene which encodes the protein ICP34.5.
- Trial name
- 1716-12 (NCT01721018)
- Testing
- HSV1716 Intra-pleural delivery
- Where
- 2 sites in United Kingdom
- Volunteers
- 12 people
- Sponsor
- Virttu Biologics Limited
Peritoneal Carcinomatosis, Pseudomyxoma Peritonei
Register With Patients in Which Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) Was Performed
The purpose of this study is to register the follow-up data of patients who, because of a peritoneal surface malignancy, will undergo cytoreductive surgery and HIPEC.
- Conditions
- Peritoneal Carcinomatosis, Pseudomyxoma Peritonei, Peritoneal Mesothelioma
- Trial name
- HIPEC (NCT01617382)
- Where
- Belgium
- Volunteers
- 125 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Malignant Pleural Mesothelioma
Nintedanib as Switch Maintenance Treatment of Pleural Malignant Mesothelioma
This is a multicenter, randomized, 1:1, double blinded phase II trial. Patients with unresectable malignant pleural mesothelioma (MPM) will be randomized between arm A: nintedanib and arm B:placebo
- Trial name
- NEMO (NCT02863055)
- Testing
- Nintedanib
- Where
- 9 sites in Belgium, Italy and 1 more
- Volunteers
- 37 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Mesothelioma
Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma
Background: Mesothelioma is a type of cancer. It originates in cells that line human body cavities. Most people have advanced disease when they are diagnosed. Researchers want to see if a combination of drugs can help.
- Trial name
- NCT04840615
- Testing
- LMB-100, ipilimumab, Diphenhydramine
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- National Cancer Institute (NCI)